Sälj aktien Köp aktien Handla aktien direkt på nordnet

« Tillbaka

Swedencare - Building a pet powerhouse

24 september 2020

Continuing the M&A journey through 2 acquisitions
Paying 10x and 12x EV/EBITDA
Proforma calculation point to ~44% ‘21e EPS accretion
Acquisition of Nutravet and Animal Pharmaceuticals
This evening, Swedencare announced the acquisitions of two companies, Nutravet and Animal Pharmaceuticals. The acquisitions are financed by cash and a share issue. Nutravet is a British vet exclusive company on a roll-out journey in Europe together with a leading vet-chain. The company has a broad product portfolio including products for dog, cat and horse health. Animal Pharmaceuticals (“AP”) is an American company very similar to Stratford Pharmaceuticals, the acquisition made during the summer. AP is strong within dermatology and sells through its own brand and private label. In our view, synergies are most apparent in the AP acquisition, where purchasing and organisational synergies with Stratford should be possible. Furthermore, Swedencare now has access to the three largest distributors in the US (two from Stratford, one from AP), creating significant revenue synergy opportunities with the ProDen Plaqueoff brand.

~44% ‘21e EPS accretion with constant financials
Nutravet lies at EBITDA margins of 51.5% and AP at 34.3%, to be compared to our forecasted 28.4% ‘21e for SECARE. Assuming no synergies or growth for the two acquisitions during H2’20 or 2021, the acquisitions would mean an accretion to our ‘21e Sales, EBITDA and EPS by 40%, 61% and 44%, respectively.

Increasing US exposure, Plaqueoff exposure down to 40%
There are multiple interesting points with these acquisitions. 1) The acquisitions approached Swedencare about being acquired. We can imagine this helped acquisition multiples stay low. If this trend continues, we see no reason why the M&A journey should stop here. 2) SECARE continues to increase the exposure towards the US, the largest pet market globally, where the average spend per pet is double the one in Europe. 3) On the same calculation as in the second paragraph, the Plaqueoff exposure is now down to ~40%. Hence, the 2021 patent risk has decreased significantly.

Senaste artiklar från alla bolag

Datum Titel Bolag Typ
2020-10-20 StrongPoint - Accelerating momentum StrongPoint Analys
2020-10-20 Flexion Mobile - Huawei drives Q2 outperformance Flexion Mobile Analys
2020-10-20 SinterCast - Difficult times, but solid outlook SinterCast Analys
2020-10-20 Avensia - Net recruitment rate should remain high... Avensia Analys
2020-10-20 ENLABS - On course to reach financial target ENLABS Analys
2020-10-19 Nilörngruppen - Delivering on cost control Nilörngruppen Analys
2020-10-16 Fortnox - ESG profile Fortnox Analys
2020-10-16 Formpipe - ESG profile Formpipe Analys
2020-10-16 SinterCast - 2019 dividend back on the agenda SinterCast Analys
2020-10-15 Nilörngruppen - Still tough, but we see light in ... Nilörngruppen Analys
2020-10-15 Doro - Announces its third M&A post summer Doro Analys
2020-10-15 Maha Energy - Guidance update reflects soft end t... Maha Energy Analys
2020-10-15 Vitec - Solid Q3’20 report from Vitec Vitec Analys
2020-10-15 GreenMobility - Getting bigger and bigger GreenMobility Analys
2020-10-14 Svedbergs - Q3 to show continued cost control Svedbergs Analys
2020-10-14 Fiskars Group - Reinstates guidance for increased... Fiskars Group Analys
2020-10-14 Maha Energy - Some operational hiccups in Q3 Maha Energy Analys
2020-10-14 Tethys Oil - Producing above quota Tethys Oil Analys
2020-10-13 Handicare - Improved Stairlift demand drives stro... Handicare Analys
2020-10-13 SinterCast - 2019 dividend back on the agenda SinterCast Analys